48
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Racial/Ethnic and Age Group Differences in Opioid and Synthetic Opioid–Involved Overdose Deaths Among Adults Aged ≥18 Years in Metropolitan Areas — United States, 2015–2017

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Among the 47,600 opioid-involved overdose deaths in the United States in 2017, 59.8% (28,466) involved synthetic opioids ( 1 ). Since 2013, synthetic opioids, particularly illicitly manufactured fentanyl (IMF), including fentanyl analogs, have been fueling the U.S. overdose epidemic ( 1 , 2 ). Although initially mixed with heroin, IMF is increasingly being found in supplies of cocaine, methamphetamine, and counterfeit prescription pills, which increases the number of populations at risk for an opioid-involved overdose ( 3 , 4 ). With the proliferation of IMF, opioid-involved overdose deaths have increased among minority populations including non-Hispanic blacks (blacks) and Hispanics, groups that have historically had low opioid-involved overdose death rates ( 5 ). In addition, metropolitan areas have experienced sharp increases in drug and opioid-involved overdose deaths since 2013 ( 6 , 7 ). This study analyzed changes in overdose death rates involving any opioid and synthetic opioids among persons aged ≥18 years during 2015–2017, by age and race/ethnicity across metropolitan areas. Nearly all racial/ethnic groups and age groups experienced increases in opioid-involved and synthetic opioid–involved overdose death rates, particularly blacks aged 45–54 years (from 19.3 to 41.9 per 100,000) and 55–64 years (from 21.8 to 42.7) in large central metro areas and non-Hispanic whites (whites) aged 25–34 years (from 36.9 to 58.3) in large fringe metro areas. Comprehensive and culturally tailored interventions are needed to address the rise in drug overdose deaths in all populations, including prevention strategies that address the risk factors for substance use across each racial/ethnic group, public health messaging to increase awareness about synthetic opioids in the drug supply, expansion of naloxone distribution for overdose reversal, and increased access to medication-assisted treatment. Drug overdose deaths were identified in the National Vital Statistics System multiple cause-of-death mortality files,* using the International Classification of Diseases, Tenth Revision (ICD-10), underlying cause-of-death codes X40–44 (unintentional), X60–64 (suicide), X85 (homicide), or Y10–Y14 (undetermined intent). These underlying cause-of-death codes identify deaths caused by acute toxicity from drugs rather than chronic exposure or adverse effects, including all intents. Among deaths with these underlying cause-of-death codes, the type of opioid involved in the drug overdose death is indicated by the following ICD-10 multiple cause-of-death codes: any opioid (T40.0, T40.1, T40.2, T40.3, T40.4, or T40.6) and synthetic opioids other than methadone (e.g., fentanyl, fentanyl analogs, and tramadol) (T40.4). Some deaths involved more than one type of opioid; these deaths were included in counts and rates for each subcategory. Thus, categories were not mutually exclusive. Crude death rates per 100,000 population for overdose deaths involving any opioid and those involving synthetic opioids were examined for 2015–2017 by age group stratified by race/ethnicity within metropolitan areas (large central metro, large fringe metro, and medium/small metro). Metropolitan area was based on the 2013 urbanization classification scheme. † Analyses comparing absolute and percentage changes in death rates from 2015 to 2017 used z-tests when deaths were ≥100 and nonoverlapping 95% confidence intervals based on a gamma distribution when deaths were <100. § Data on synthetic opioid-involved overdose deaths by race/ethnicity and age group within nonmetropolitan areas as well as deaths among non-Hispanic American Indian/Alaska Natives, non-Hispanic Asian Americans, and persons aged <18 years were almost universally suppressed because of small numbers of deaths ¶ ; thus, they were not included in the analysis. From 2015 to 2017, death rates for drug overdoses involving any opioid and synthetic opioids increased across all racial/ethnic groups in each metropolitan area (Table 1). In large central metro areas, blacks experienced the largest absolute and percentage increases in rates of drug overdose deaths involving any opioid or synthetic opioids, with rates for deaths involving any opioid increasing 103% (from 11.8 to 24.0 per 100,000, absolute increase of 12.2), and for deaths involving synthetic opioids increasing 361% (from 3.6 to 16.6; absolute increase of 13.0). In large fringe metro areas, whites experienced the largest absolute increases rates of overdose deaths involving any opioid (from 17.8 to 26.7, absolute increase of 8.9) and those involving synthetic opioids (from 6.1 to 17.5, absolute increase of 11.4); blacks experienced the largest percentage change in drug overdose death rates involving any opioid (100%, from 7.2 to 14.4) and for overdose deaths involving synthetic opioids (332%, from 2.5 to 10.8). In medium/small metro areas, for overdose deaths involving any opioid, blacks experienced the largest percentage (82%) and absolute increase (6.0; from 7.3 to 13.3) in rates; whites had the largest absolute increase in rates of overdose deaths involving synthetic opioids (from 4.8 to 12.6, absolute increase of 7.8), and Hispanics** had the largest percentage increase in rates of drug overdose deaths involving synthetic opioids (262%, from 1.3 to 4.7). TABLE 1 Opioid-involved overdose death rates and synthetic opioid–involved overdose death rates* among adults aged ≥18 years, by urbanization level, † race/ethnicity, § and age group — National Vital Statistics System, United States, 2015–2017 Urbanization, Race/Ethnicity, Age Group (yrs) Opioid-involved overdose deaths Opioid-involved overdose deaths involving synthetic opioids 2015
no. (rate) 2016
no. (rate) 2017
no. (rate) Absolute rate change¶ % Rate change¶ 2015
no. (rate) 2016
no. (rate) 2017
no. (rate) Absolute rate change¶ % Rate change¶ Large central metro Black, overall 1,518 (11.8) 2,503 (19.3) 3,161 (24.0) 12.2** 103** 464 (3.6) 1,430 (11.0) 2,186 (16.6) 13.0** 361** 18–24 68 (3.6) 112 (6.0) 113 (6.2) 2.6** 72** 23 (1.2) 54 (2.9) 80 (4.4) 3.2** 267** 25–34 225 (8.6) 368 (13.6) 462 (16.5) 7.9** 92** 79 (3.0) 221 (8.1) 325 (11.6) 8.6** 287** 35–44 255 (11.5) 417 (18.9) 532 (23.9) 12.4** 108** 71 (3.2) 231 (10.5) 354 (15.9) 12.7** 397** 45–54 437 (19.3) 730 (32.5) 934 (41.9) 22.6** 117** 130 (5.7) 451 (20.1) 654 (29.4) 23.7** 416** 55–64 437 (21.8) 706 (34.6) 885 (42.7) 20.9** 96** 139 (6.9) 388 (19.0) 619 (29.8) 22.9** 332** ≥65 96 (5.2) 170 (8.8) 235 (11.6) 6.4** 123** 22 (1.2) 85 (4.4) 154 (7.6) 6.4** 533** White, overall 6,636 (18.2) 8,251 (22.6) 8,989 (24.6) 6.4** 35** 1,743 (4.7) 3,633 (9.9) 5,038 (13.7) 9.0** 192** 18–24 591 (16.6) 721 (20.7) 703 (20.5) 3.9** 24** 176 (4.9) 324 (9.3) 421 (12.3) 7.4** 149** 25–34 1,736 (24.8) 2,271 (32.2) 2,484 (35.2) 10.4** 42** 531 (7.6) 1,160 (16.4) 1,560 (22.1) 14.5** 191** 35–44 1,360 (24.2) 1,812 (32.4) 2,039 (36.3) 12.1** 50** 378 (6.7) 902 (16.1) 1,253 (22.3) 15.6** 232** 45–54 1,503 (24.1) 1,768 (29.0) 1,908 (32.1) 8.0** 33** 362 (5.8) 726 (11.9) 1,034 (17.4) 11.6** 199** 55–64 1,156 (18.2) 1,369 (21.5) 1,462 (23.0) 4.8** 26** 239 (3.8) 447 (7.0) 657 (10.3) 6.5** 174** ≥65 290 (3.8) 310 (3.9) 393 (4.8) 1.0** 26** 57 (0.7) 74 (0.9) 113 (1.4) 0.7** 100** Hispanic, overall†† 1,176 (6.2) 1,674 (8.8) 1,901 (9.7) 3.5** 57** 238 (1.3) 766 (4.0) 1,058 (5.4) 4.2** 350** 18–24 152 (4.9) 202 (6.5) 234 (7.6) 2.7** 55** 26 (0.8) 82 (2.7) 132 (4.3) 3.5** 438** 25–34 297 (6.8) 440 (9.9) 512 (11.2) 4.4** 65** 68 (1.5) 203 (4.6) 289 (6.3) 4.8** 320** 35–44 287 (7.2) 419 (10.5) 458 (11.3) 4.1** 57** 58 (1.5) 212 (5.3) 271 (6.7) 5.2** 347** 45–54 256 (7.8) 360 (10.8) 420 (12.3) 4.5** 58** 54 (1.7) 173 (5.2) 235 (6.9) 5.2** 306** 55–64 151 (7.0) 219 (9.8) 223 (9.5) 2.5** 36** 26 (1.2) 90 (4.0) 106 (4.5) 3.3** 275** ≥65 33 (1.7) 34 (1.7) 54 (2.5) 0.8 47 —§§ — 25 (1.2) — — Large fringe metro Black, overall 519 (7.2) 906 (12.3) 1,086 (14.4) 7.2** 100** 179 (2.5) 499 (6.8) 812 (10.8) 8.3** 332** 18–24 48 (4.4) 87 (8.1) 88 (8.1) 3.7** 84** 20 (1.8) 56 (5.2) 62 (5.7) 3.9** 217** 25–34 102 (7.3) 220 (15.3) 273 (18.2) 10.9** 149** 44 (3.2) 130 (9.0) 205 (13.7) 10.5** 328** 35–44 132 (9.9) 193 (14.4) 249 (18.2) 8.3** 84** 47 (3.5) 108 (8.0) 197 (14.4) 10.9** 311** 45–54 127 (9.3) 232 (16.8) 258 (18.4) 9.1** 98** 36 (2.6) 118 (8.5) 184 (13.1) 10.5** 404** 55–64 99 (9.2) 140 (12.5) 184 (15.8) 6.6** 72** 30 (2.8) 71 (6.3) 137 (11.7) 8.9** 318** ≥65 11 (—) 34 (3.4) 34 (3.3) — — — 16 (—) 27 (2.6) — — White, overall 7,561 (17.8) 10,179 (23.8) 11,442 (26.7) 8.9** 50** 2,594 (6.1) 5,292 (12.4) 7,486 (17.5) 11.4** 187** 18–24 801 (18.5) 1,106 (25.8) 1,097 (25.9) 7.4** 40** 303 (7.0) 620 (14.5) 778 (18.4) 11.4** 163** 25–34 2,283 (36.9) 3,177 (50.9) 3,658 (58.3) 21.4** 58** 901 (14.6) 1,887 (30.3) 2,666 (42.5) 27.9** 191** 35–44 1,738 (26.9) 2,392 (37.5) 2,699 (42.4) 15.5** 58** 628 (9.7) 1,318 (20.7) 1,874 (29.4) 19.7** 203** 45–54 1,644 (20.2) 2,009 (25.1) 2,274 (29.2) 9.0** 45** 501 (6.1) 925 (11.6) 1,363 (17.5) 11.4** 187** 55–64 911 (11.4) 1,260 (15.6) 1,433 (17.6) 6.2** 54** 223 (2.8) 475 (5.9) 701 (8.6) 5.8** 207** ≥65 184 (1.9) 235 (2.4) 281 (2.8) 0.9** 47** 38 (0.4) 67 (0.7) 104 (1.0) 0.6** 150** Hispanic, overall†† 423 (5.7) 674 (8.9) 790 (10.0) 4.3** 75** 123 (1.7) 362 (4.8) 531 (6.7) 5.0** 294** 18–24 65 (5.2) 94 (7.5) 95 (7.4) 2.2** 42** 21 (1.7) 48 (3.8) 61 (4.7) 3.0** 177** 25–34 128 (7.5) 214 (12.4) 243 (13.6) 6.1** 81** 44 (2.6) 131 (7.6) 165 (9.2) 6.6** 254** 35–44 119 (7.0) 194 (11.2) 210 (11.7) 4.7** 67** 33 (1.9) 106 (6.1) 149 (8.3) 6.4** 337** 45–54 71 (5.4) 129 (9.5) 157 (11.1) 5.7** 106** 20 (1.5) 58 (4.3) 114 (8.0) 6.5** 433** 55–64 33 (4.1) 37 (4.4) 73 (8.1) 4.0** 98** — 19 (—) 37 (4.1) — — ≥65 — — 12 (—) — — — — — — — Medium and small metro Black, overall 553 (7.3) 776 (10.1) 1,036 (13.3) 6.0** 82** 199 (2.6) 387 (5.0) 698 (8.9) 6.3** 242** 18–24 36 (2.6) 57 (4.2) 83 (6.2) 3.6** 139** 21 (1.5) 27 (2.0) 54 (4.0) 2.5** 167** 25–34 111 (7.2) 183 (11.6) 231 (14.2) 7.0** 97** 39 (2.5) 99 (6.3) 176 (10.8) 8.3** 332** 35–44 146 (11.4) 193 (15.0) 267 (20.5) 9.1** 80** 55 (4.3) 100 (7.8) 186 (14.3) 10.0** 233** 45–54 139 (11.0) 154 (12.2) 219 (17.5) 6.5** 59** 48 (3.8) 78 (6.2) 149 (11.9) 8.1** 213** 55–64 99 (8.7) 153 (13.2) 187 (15.8) 7.1** 82** 30 (2.6) 72 (6.2) 110 (9.3) 6.7** 258** ≥65 22 (2.2) 36 (3.4) 49 (4.4) 2.2** 100** — 11 (—) 23 (2.1) — — White, overall 8,794 (16.4) 10,530 (19.6) 11,767 (21.9) 5.5** 34** 2,547 (4.8) 4,449 (8.3) 6,803 (12.6) 7.8** 163** 18–24 757 (11.7) 943 (14.9) 960 (15.4) 3.7** 32** 260 (4.0) 433 (6.8) 634 (10.2) 6.2** 155** 25–34 2,270 (27.7) 2,963 (35.9) 3,324 (40.2) 12.5** 45** 772 (9.4) 1,454 (17.6) 2,203 (26.6) 17.2** 183** 35–44 2,042 (26.9) 2,552 (33.9) 2,892 (38.3) 11.4** 42** 634 (8.4) 1,188 (15.8) 1,816 (24.1) 15.7** 187** 45–54 2,032 (22.6) 2,228 (25.2) 2,475 (28.7) 6.1** 27** 530 (5.9) 867 (9.8) 1,326 (15.4) 9.5** 161** 55–64 1,349 (14.0) 1,450 (14.9) 1,706 (17.5) 3.5** 25** 292 (3.0) 415 (4.3) 733 (7.5) 4.5** 150** ≥65 344 (2.7) 394 (3.0) 410 (3.1) 0.4 15 59 (0.5) 92 (0.7) 91 (0.7) 0.2** 40** Hispanic, overall†† 709 (7.3) 870 (8.8) 1,012 (9.9) 2.6** 36** 127 (1.3) 321 (3.2) 485 (4.7) 3.4** 262** 18–24 78 (4.2) 110 (5.9) 111 (5.8) 1.6** 38** 20 (1.1) 40 (2.1) 59 (3.1) 2.0** 182** 25–34 196 (8.6) 250 (10.8) 298 (12.5) 3.9** 45** 33 (1.4) 88 (3.8) 159 (6.7) 5.3** 379** 35–44 184 (9.2) 231 (11.4) 270 (12.9) 3.7** 40** 37 (1.9) 103 (5.1) 138 (6.6) 4.7** 247** 45–54 159 (10.2) 166 (10.4) 199 (12.1) 1.9 19 29 (1.9) 57 (3.6) 87 (5.3) 3.4** 179** 55–64 77 (7.3) 93 (8.4) 117 (10.1) 2.8** 39** — 29 (2.6) 38 (3.3) — — ≥65 15 (—) 20 (2.0) 17 (—) — — — — — — — * Deaths were classified using the International Classification of Diseases, Tenth Revision (ICD-10). Opioid-involved overdose deaths were identified using underlying cause-of-death codes X40–44, X60–64, X85, and Y10–14. Among deaths with overdose as the underlying cause, the type of drug involved in the overdose death was indicated by the following ICD-10 multiple cause-of-death codes: any opioid (T40.0, T40.1, T40.2, T40.3, T40.4, or T40.6) and synthetic opioids other than methadone (T40.4). Totals for deaths by category might involve more than one drug other than synthetic opioids. Rates displayed are age-specific crude rates per 100,000 persons. † Based on the 2013 urbanization classification (https://www.cdc.gov/nchs/data_access/urban_rural.htm). Large central metro: counties in metropolitan statistical areas (MSAs) of ≥1 million population that 1) contain the entire population of the largest principal city of the MSA, or 2) have their entire population contained in the largest principal city of the MSA, or 3) contain at least 250,000 inhabitants of any principal city of the MSA. Large fringe metro: counties in the MSAs of ≥1 million population that did not qualify as large central metro counties. Medium metro: counties in MSAs of populations of 250,000–999,999. Small metro: counties in MSAs of populations <250,000. Because of low numbers of deaths and rate suppression for key populations, micropolitan areas (nonmetropolitan counties) and noncore areas (counties that did not qualify as micropolitan) were not included in this analysis. § Blacks and whites are non-Hispanic; Hispanic persons can be of any race. ¶ Absolute rate change is the difference between the 2015 and 2017 rates. Percent change in rate is calculated as the absolute rate change divided by the 2015 rate, multiplied by 100. Statistical significance was determined using nonoverlapping 95% confidence intervals (CIs) based on the gamma method if the number of deaths was <100 in 2015 and 2017, and z-tests were used if the number of deaths was ≥100 in 2015 and 2017. Percent changes were rounded to the nearest whole number. The method of comparing CIs is a conservative method for statistical significance, and caution should be used when interpreting a nonsignificant difference when the lower and upper bounds being compared only slightly overlap. ** p<0.05 using z-tests when deaths were ≥100 or when deaths were <100; nonoverlapping 95% CIs based on a gamma distribution. †† Data for Hispanic origin should be interpreted with caution; studies comparing Hispanic origin on death certificates and on census surveys have indicated that reporting on Hispanic ethnicity is inconsistent. https://www.cdc.gov/nchs/data/series/sr_02/sr02_172.pdf. §§ Dashes indicate that result is suppressed because <10 deaths, and rates based on <20 deaths are considered unreliable. Absolute and percent changes in rates cannot be calculated for these values. Examining death rates for drug overdose deaths involving any opioid or synthetic opioids by racial/ethnic age groups in large central metro areas found that the highest drug overdose death rates involving any opioid (42.7) and synthetic opioids (29.8) in 2017 were among blacks aged 55–64 years (Table 1). From 2015 to 2017, blacks aged 45–54 years in large central metro areas experienced the largest absolute increase in death rates involving any opioid (from 19.3 to 41.9, absolute increase of 22.6) and synthetic opioids (from 5.7 to 29.4, absolute increase of 23.7), and blacks aged ≥65 years in these areas had the largest percentage increases in rates of drug overdose deaths involving any opioid (123%; from 5.2 to 11.6) and synthetic opioids (533%; from 1.2 to 7.6). Among racial/ethnic age groups in large fringe metro areas, in 2017, the highest rates of drug overdose deaths involving any opioid (58.3) and synthetic opioids (42.5) were in whites aged 25–34 years (Table 1); this group also experienced the largest absolute increases in death rates involving any opioid (from 36.9 to 58.3; absolute increase of 21.4) and synthetic opioids (from 14.6 to 42.5; absolute increase of 27.9) in these areas from 2015 to 2017. The largest percentage increase in rates of drug overdose deaths involving any opioid in large fringe metro areas from 2015 to 2017 occurred among blacks aged 25–34 years (149%; from 7.3 to 18.2), and the largest percentage increase in overdose death rates involving synthetic opioids was in Hispanics aged 45–54 years (433%; from 1.5 to 8.0). Among racial/ethnic age groups in medium/small metro areas, in 2017, the highest rates of drug overdose deaths involving any opioid or synthetic opioids were in whites aged 25–34 years (40.2 and 26.6, respectively). This group also experienced the largest absolute increases in drug overdose death rates involving any opioid (from 27.7 to 40.2, absolute increase of 12.5) and synthetic opioids (from 9.4 to 26.6, absolute increase of 17.2) in these areas from 2015 to 2017 (Table 1). From 2015 to 2017, blacks aged 18–24 years experienced the largest percentage increase in opioid-involved overdose death rates (139%; from 2.6 to 6.2); the largest percentage increase in synthetic opioid–involved overdose death rates (379%; from 1.4 to 6.7) occurred among Hispanics aged 25–34 years. The percentage of all opioid-involved overdose deaths involving synthetic opioids increased from 2015 to 2017 across all racial/ethnic age groups in each metropolitan area category (Table 2). By 2017, the greatest level of synthetic opioid involvement in opioid-involved overdose deaths was among blacks in all metro areas and ranged from 67.4% in medium/small metro areas to 74.8% in large fringe metro areas. Among whites, the percentage of opioid-involved overdose deaths involving synthetic opioids ranged from 56.0% in large central metro areas to 65.4% in large fringe metro areas. Among Hispanics, the percentage of opioid-involved overdose deaths involving synthetic opioids ranged from 47.9% in medium/small metro areas to 67.2% in large fringe metro areas. TABLE 2 Percentage of opioid-involved overdose deaths* involving synthetic opioids among adults aged ≥18 years, by urbanization level, age group, and race/ethnicity, — National Vital Statistics System, United States, 2015–2017 Urbanization level† Age group (yrs) Race/Ethnicity§,¶ Year, % 2015 2016 2017 % Increase, 2015–2017**,†† Large central metro All Black 30.6 57.1 69.2 126 White 26.1 44.0 56.0 115 Hispanic 20.2 45.8 55.7 175 18–24 Black 33.8 48.2 70.8 109 White 29.8 44.9 59.9 101 Hispanic 17.1 40.6 56.4 230 25–34 Black 35.1 60.1 70.3 100 White 30.6 51.1 62.8 105 Hispanic 22.9 46.1 56.4 147 35–44 Black 27.8 55.4 66.5 139 White 27.8 49.8 61.5 121 Hispanic 20.2 50.6 59.2 193 45–54 Black 29.7 61.8 70.0 135 White 24.1 41.1 54.2 125 Hispanic 21.1 48.1 56.0 165 55–64 Black 31.8 55.0 69.9 120 White 20.7 32.7 44.9 117 Hispanic 17.2 41.1 47.5 176 ≥65 Black 22.9 50.0 65.5 186 White 19.7 23.9 28.8 46 Hispanic —§§ — 46.3 — Large fringe metro All Black 34.5 55.1 74.8 117 White 34.3 52.0 65.4 91 Hispanic 29.1 53.7 67.2 131 18–24 Black 41.7 64.4 70.5 69 White 37.8 56.1 70.9 88 Hispanic 32.3 51.1 64.2 99 25–34 Black 43.1 59.1 75.1 74 White 39.5 59.4 72.9 85 Hispanic 34.4 61.2 67.9 98 35–44 Black 35.6 56.0 79.1 122 White 36.1 55.1 69.4 92 Hispanic 27.7 54.6 71.0 156 45–54 Black 28.3 50.9 71.3 152 White 30.5 46.0 59.9 97 Hispanic 28.2 45.0 72.6 158 55–64 Black 30.3 50.7 74.5 146 White 24.5 37.7 48.9 100 Hispanic — — 50.7 — ≥65 Black — — 79.4 — White 20.7 28.5 37.0 79 Hispanic — — — — Medium and small metro All Black 36.0 49.9 67.4 87 White 29.0 42.3 57.8 100 Hispanic 17.9 36.9 47.9 168 18–24 Black 58.3 47.4 65.1 12 White 34.3 45.9 66.0 92 Hispanic 25.6 36.4 53.2 108 25–34 Black 35.1 54.1 76.2 117 White 34.0 49.1 66.3 95 Hispanic 16.8 35.2 53.4 217 35–44 Black 37.7 51.8 69.7 85 White 31.0 46.6 62.8 102 Hispanic 20.1 44.6 51.1 154 45–54 Black 34.5 50.6 68.0 97 White 26.1 38.9 53.6 106 Hispanic 18.2 34.3 43.7 140 55–64 Black 30.3 47.1 58.8 94 White 21.6 28.6 43.0 99 Hispanic — 31.2 32.5 — ≥65 Black — — 46.9 — White 17.2 23.4 22.2 29 Hispanic — — — — * Deaths were classified using the International Classification of Diseases, Tenth Revision (ICD-10). Opioid-involved overdose deaths were identified using underlying cause-of-death codes X40–44, X60–64, X85, and Y10–14. Among deaths with overdose as the underlying cause, the type of drug involved in the overdose death was indicated by the following ICD-10 multiple cause-of-death codes: any opioid (T40.0, T40.1, T40.2, T40.3, T40.4, or T40.6) and synthetic opioids other than methadone (T40.4). Totals for deaths by category might involve more than one drug other than synthetic opioids. The percentage of opioid-involved overdose deaths involving synthetic opioids was calculated by dividing the number of opioid-involved overdose deaths involving synthetic opioids by the number of opioid-involved overdose deaths, then multiplying by 100. † Based on the 2013 urbanization classification (https://www.cdc.gov/nchs/data_access/urban_rural.htm). Large central metro: counties in metropolitan statistical areas (MSAs) of ≥1 million population that 1) contain the entire population of the largest principal city of the MSA, or 2) have their entire population contained in the largest principal city of the MSA, or 3) contain at least 250,000 inhabitants of any principal city of the MSA. Large fringe metro: counties in the MSAs of ≥1 million population that did not qualify as large central metro counties. Medium metro: counties in MSAs of populations of 250,000–999,999. Small metro: counties in MSAs of populations <250,000. Because of low numbers of deaths and rate suppression for key populations, micropolitan areas (nonmetropolitan counties) and noncore areas (counties that did not qualify as micropolitan) were not included in this analysis. § Blacks and whites were non-Hispanic; Hispanics could be of any race. ¶ Data for Hispanic origin should be interpreted with caution; studies comparing Hispanic origin on death certificates and on census surveys have indicated that reporting on Hispanic ethnicity is inconsistent. https://www.cdc.gov/nchs/data/series/sr_02/sr02_172.pdf. ** Percentage increase in opioid-involved overdose deaths involving synthetic opioids was calculated by subtracting the percentage of deaths that involved synthetic opioids in 2017 from the percentage of deaths involving synthetic opioids in 2015, dividing this value by the percentage of deaths involving synthetic opioids in 2015, and then multiplying by 100. †† Total percent changes were rounded to the nearest whole number. §§ Dashes indicate that percent change in synthetic opioid involvement in opioid-involved overdose deaths could not be calculated because of unreliable rates or suppression. Discussion Synthetic opioids are driving the recent increases in opioid-involved overdose deaths in the United States. Previous research has found that synthetic opioids were involved in nearly 60% of opioid-involved overdose deaths in the United States in 2017 ( 1 ); this study examines the variation in synthetic opioid involvement in these deaths among racial/ethnic age groups across different metropolitan areas. For example, in large central metro areas, among persons aged 45–54 years, synthetic opioids were involved in 70.0% of all opioid-involved overdose deaths among blacks, 54.2% among whites, and 56.0% among Hispanics. These findings underscore the changing demographics and populations affected by the opioid overdose epidemic as the illicit drug supply continues to evolve. Consistent with these findings, a recent report by the New York City Department of Health and Mental Hygiene ( 8 ) identified high rates of drug overdoses in 2017 involving heroin or fentanyl among middle-aged and older-aged blacks and Hispanics in a large metropolitan area infiltrated by IMF in recent years; these rates have largely eclipsed those among whites of the same age ( 9 ). The distinct age distributions of opioid-involved overdose deaths between the racial/ethnic age groups and different metropolitan areas highlight the heterogeneity that exists among persons who use drugs, illicit drug markets, and risk factors for overdose. Differences in opioid prescribing rates, underlying rates of opioid and other substance use disorders, access to substance use disorder treatment, and the proliferation of IMF in the illicit drug supply might all underlie the unique patterns of opioid-involved overdose deaths observed in this study. Thus, additional efforts are needed to develop and implement prevention, treatment, and response strategies that are tailored to diverse racial/ethnic and age groups within specific community contexts. In addition, more research is needed to explore the underlying drivers of differing overdose risk among racial/ethnic age groups across metropolitan areas. The findings in this report are subject to at least four limitations. First, numbers and rates of deaths involving specific drugs might be affected by factors related to death investigations, such as the substances tested for or the circumstances under which these tests are performed. Second, changes in fentanyl or other synthetic opioid testing and reporting as well as the percentage of deaths with specific drugs listed on the death certificate have changed over the study period and might have contributed to the observed increases in opioid- and synthetic opioid–involved overdose deaths. †† Third, potential racial or ethnic misclassification might lead to underestimates or overestimates for certain groups. Finally, because of small numbers of synthetic opioid–involved overdose deaths among certain racial/ethnic groups, persons aged <18 years, and in nonmetropolitan areas, data on these populations were not included in this report. Thus, exploration of how synthetic opioids are affecting these populations is beyond the scope of this report. The changing patterns of the opioid overdose epidemic necessitate a rapid, culturally tailored and multifaceted public health response that appropriately targets and incorporates the needs of evolving populations at risk, including minority populations that historically have been regarded as having low opioid-involved overdose death rates. Curbing the opioid overdose epidemic requires collaborations across all sectors of government, law enforcement, public health, and communities. This study emphasizes the importance of data-informed approaches to addressing the evolving needs of communities and highlights the need for timely data that can be used to effectively guide public health responses. Prevention and response strategies include public health messaging campaigns to increase awareness about illicit synthetic opioids in the drug supply, naloxone distribution that targets both persons who knowingly use opioids and those who might be exposed to opioids through contamination of other illicit drugs, the expansion of and equitable access to medication-assisted treatment for opioid use disorder, evidence-based treatment for other substance use disorders, and recovery support services for persons with substance use disorders. Importantly, cultural, language, and structural barriers that minority populations might face should be considered as these interventions are being developed and implemented. Summary What is already known about this topic? Opioid-involved overdose death rates in the United States differ by demographic and geographic characteristics. Illicitly manufactured fentanyl and fentanyl analogs have fueled recent increases in opioid-involved overdose deaths. In 2017, synthetic opioids were involved in nearly 60% of opioid-involved overdose deaths; however, the level of involvement by racial/ethnic age groups in metropolitan areas has not been explored. What is added by this report? From 2015 to 2017, nearly all racial/ethnic groups and age groups experienced significant increases in opioid-involved and synthetic opioid–involved overdose death rates, particularly blacks aged 45–54 years (from 19.3 to 41.9 per 100,000) and 55–64 years (from 21.8 to 42.7) in large central metro areas. The increased involvement of synthetic opioids in overdose deaths is changing the demographics of the opioid overdose epidemic. What are the implications for public health practice? Culturally competent interventions are needed to target populations at risk; these interventions include increasing awareness about synthetic opioids in the drug supply and expanding evidence-based interventions, such as naloxone distribution and medication-assisted treatment.

          Related collections

          Most cited references7

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017

          The 63,632 drug overdose deaths in the United States in 2016 represented a 21.4% increase from 2015; two thirds of these deaths involved an opioid ( 1 ). From 2015 to 2016, drug overdose deaths increased in all drug categories examined; the largest increase occurred among deaths involving synthetic opioids other than methadone (synthetic opioids), which includes illicitly manufactured fentanyl (IMF) ( 1 ). Since 2013, driven largely by IMF, including fentanyl analogs ( 2 – 4 ), the current wave of the opioid overdose epidemic has been marked by increases in deaths involving synthetic opioids. IMF has contributed to increases in overdose deaths, with geographic differences reported ( 1 ). CDC examined state-level changes in death rates involving all drug overdoses in 50 states and the District of Columbia (DC) and those involving synthetic opioids in 20 states, during 2013–2017. In addition, changes in death rates from 2016 to 2017 involving all opioids and opioid subcategories,* were examined by demographics, county urbanization levels, and by 34 states and DC. Among 70,237 drug overdose deaths in 2017, 47,600 (67.8%) involved an opioid. † From 2013 to 2017, drug overdose death rates increased in 35 of 50 states and DC, and significant increases in death rates involving synthetic opioids occurred in 15 of 20 states, likely driven by IMF ( 2 , 3 ). From 2016 to 2017, overdose deaths involving all opioids and synthetic opioids increased, but deaths involving prescription opioids and heroin remained stable. The opioid overdose epidemic continues to worsen and evolve because of the continuing increase in deaths involving synthetic opioids. Provisional data from 2018 indicate potential improvements in some drug overdose indicators; § however, analysis of final data from 2018 is necessary for confirmation. More timely and comprehensive surveillance data are essential to inform efforts to prevent and respond to opioid overdoses; intensified prevention and response measures are urgently needed to curb deaths involving prescription and illicit opioids, specifically IMF. Drug overdose deaths were identified in the National Vital Statistics System multiple cause-of-death mortality files, ¶ with death certificate data coded using the International Classification of Diseases, Tenth Revision (ICD-10) codes X40–44 (unintentional), X60–64 (suicide), X85 (homicide), or Y10–Y14 (undetermined intent). Among deaths with drug overdose as the underlying cause, the type of drug or drug category is indicated by the following ICD-10 multiple cause-of-death codes: opioids (T40.0, T40.1, T40.2, T40.3, T40.4, or T40.6)**; natural/semisynthetic opioids (T40.2); methadone (T40.3); heroin (T40.1); synthetic opioids other than methadone (T40.4); cocaine (T40.5); and psychostimulants with abuse potential (T43.6). †† Some deaths involved more than one type of drug, and these were included in rates for each drug category; thus, categories are not mutually exclusive. §§ Annual percent change with statistically significant trends in age-adjusted drug overdose death rates ¶¶ for all 50 states and DC from 2013 to 2017 and in age-adjusted death rates involving synthetic opioids for 20 states that met drug specificity criteria*** were analyzed using Joinpoint regression. ††† Age-adjusted overdose death rates were examined from 2016 to 2017 for all opioids, prescription opioids ( 5 ), heroin, and synthetic opioids. Death rates were stratified by age, sex, racial/ethnic group, urbanization level, §§§ and state. State-level analyses included DC and 34 states with adequate drug specificity data for 2016 and 2017. ¶¶¶ Analyses comparing changes in death rates from 2016 to 2017 used z-tests when the number of deaths was ≥100 and nonoverlapping confidence intervals based on a gamma distribution when the number was 80% of drug overdose death certificates named at least one specific drug in 2013–2017; 2) change from 2013 to 2017 in the percentage of death certificates reporting at least one specific drug was <10 percentage points; and 3) ≥20 deaths involving synthetic opioids other than methadone occurred each year during 2013–2017. States whose reporting of any specific drug or drugs involved in an overdose changed by ≥10 percentage points from 2013 to 2017 were excluded because drug-specific overdose numbers and rates might have changed substantially from 2013 to 2017 as a result of changes in reporting. ¶ Left panel: Joinpoint regression examining changes in trends from 2013 to 2017 indicated that 35 states and the District of Columbia had significant increases in drug overdose death rates from 2013 to 2017 (Alabama, Alaska, Arizona, Arkansas, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Vermont, Virginia, Washington, West Virginia, and Wisconsin). All remaining states had nonsignificant trends during this period. Right panel: Joinpoint regression examining changes in trends from 2013 to 2017 indicated that 15 states had significant increases in death rates for overdoses involving synthetic opioids other than methadone from 2013 to 2017 (Connecticut, Illinois, Iowa, Maine, Maryland, Minnesota, Nevada, New York, North Carolina, Oregon, Rhode Island, Virginia, Washington, West Virginia, and Wisconsin). The five remaining states analyzed had nonsignificant trends during this period. Significant increases in trends were not detected in some states with large absolute increases in death rates from 2013 to 2017 because of limited power to detect significant effects. The figure shows age-adjusted rates of drug overdose deaths and deaths involving synthetic opioids other than methadone, by state in the United States during 2013 and 2017. From 2016 to 2017, opioid-involved overdose deaths increased among males and females and among persons aged ≥25 years, non-Hispanic whites (whites), non-Hispanic blacks (blacks), and Hispanics (Table 1). The largest relative change occurred among blacks (25.2%), and the largest absolute rate increase was among males aged 25–44 years (an increase of 4.6 per 100,000). The largest relative change among age groups was for persons aged ≥65 years (17.2%). Counties in medium metro areas experienced the largest absolute rate increase (an increase of 1.9 per 100,000), and the largest relative rate increase occurred in micropolitan counties (14.9%). Death rates increased significantly in 15 states, with the largest relative changes in North Carolina (28.6%), Ohio (19.1%), and Maine (18.7%). From 2016 to 2017, the prescription opioid-involved death rate decreased 13.2% among males aged 15–24 years but increased 10.5% among persons aged ≥65 years (Table 1). These death rates remained stable from 2016 to 2017 across all racial groups and urbanization levels and in most states, although five states (Maine, Maryland, Oklahoma, Tennessee, and Washington) experienced significant decreases, and one (Illinois) had a significant increase. The largest relative changes included a 29.7% increase in Illinois and a 39.2% decrease in Maine. The highest prescription opioid-involved death rates in 2017 were in West Virginia (17.2 per 100,000), Maryland (11.5), and Utah (10.8). Heroin-involved overdose death rates declined among many groups in 2017 compared with those in 2016 (Table 2). The largest declines occurred among persons aged 15–24 years (15.0%), particularly males (17.5%), as well as in medium metro counties (6.1%). Rates declined 3.2% among whites. However, heroin-involved overdose death rates did increase among some groups; the largest relative rate increase occurred among persons aged ≥65 years (16.7%) and 55–64 years (11.6%) and among blacks (8.9%). Rates remained stable in most states, with significant decreases in five states (Maryland, Massachusetts, Minnesota, Missouri, and Ohio), and increases in three (California, Illinois, and Virginia). The largest relative decrease (31.9%) was in Ohio, and the largest relative increase (21.8%) was in Virginia. The highest heroin-involved overdose death rates in 2017 were in DC (18.0 per 100,000), West Virginia (14.9), and Connecticut (12.4). Deaths involving synthetic opioids propelled increases from 2016 to 2017 across all demographic categories (Table 2). The highest death rate was in males aged 25–44 years (27.0 per 100,000), and the largest relative increases occurred among blacks (60.7%) and American Indian/Alaska Natives (58.5%). Deaths increased across all urbanization levels from 2016 to 2017. Twenty-three states and DC experienced significant increases in synthetic opioid-involved overdose death rates, including eight states west of the Mississippi River. The largest relative rate increase occurred in Arizona (122.2%), followed by North Carolina (112.9%) and Oregon (90.9%). The highest synthetic opioid-involved overdose death rates in 2017 were in West Virginia (37.4 per 100,000), Ohio (32.4), and New Hampshire (30.4). Discussion In the United States, drug overdoses resulted in 702,568 deaths during 1999–2017, with 399,230 (56.8%) involving opioids. †††† From 2016 to 2017, death rates from all opioids increased, with increases driven by synthetic opioids. Deaths involving IMF have been seen primarily east of the Mississippi River; §§§§ however, recent increases occurred in eight states west of the Mississippi River, including Arizona, California, Colorado, Minnesota, Missouri, Oregon, Texas, and Washington. Drug overdose death rates from 2013 to 2017 increased in most states; the influence of synthetic opioids on these rate increases was seen in approximately one quarter of all states during this same 5-year period. Overdose deaths involving cocaine and psychostimulants also have increased in recent years ( 1 , 6 ). Overall, the overdose epidemic continues to worsen, and it has grown increasingly complex by co-involvement of prescription and illicit drugs ( 7 , 8 ). ¶¶¶¶ For example, in 2016, synthetic opioids (primarily IMF) were involved in 23.7% of deaths involving prescription opioids, 37.4% involving heroin, and 40.3% involving cocaine ( 9 ). In addition, death rates are increasing across multiple demographic groups. For example, although death rates involving opioids remained highest among whites, relatively large increases across several drug categories were observed among blacks. The findings in this report are subject to at least five limitations. First, at autopsy, substances tested for vary by time and jurisdiction, and improvements in toxicologic testing might account for some reported increases. Second, the specific types of drugs involved were not included on 15% of drug overdose death certificates in 2016 and 12% in 2017, and the percentage of death certificates with at least one drug specified ranged among states from 54.7%–99.3% in 2017, limiting rate comparisons between states. Third, because heroin and morphine are metabolized similarly ( 10 ), some heroin deaths might have been misclassified as morphine deaths, resulting in underreporting of heroin deaths. Fourth, potential race misclassification might have led to underestimates for certain categories, primarily for American Indian/Alaska Natives and Asian/Pacific Islanders.***** Finally, most state-specific analyses were restricted to DC and a subset of states with adequate drug specificity, limiting generalizability. Through 2017, the drug overdose epidemic continues to worsen and evolve, and the involvement of many types of drugs (e.g., opioids, cocaine, and methamphetamine) underscores the urgency to obtain more timely and local data to inform public health and public safety action. Although prescription opioid- and heroin-involved death rates were stable from 2016 to 2017, they remained high. Some preliminary indicators in 2018 point to possible improvements based on provisional data; ††††† however, confirmation will depend on results of pending medical investigations and analysis of final data. Overall, deaths involving synthetic opioids continue to drive increases in overdose deaths. CDC funds 32 states and DC to collect more timely and comprehensive drug overdose data, including improved toxicologic testing in opioid-involved fatal overdoses. §§§§§ CDC is funding prevention activities in 42 states and DC. ¶¶¶¶¶ CDC also is leveraging emergency funding to support 49 states, DC, and four territories to broaden their surveillance and response capabilities and enable comprehensive community-level responses with implementation of novel, evidence-based interventions.****** Continued efforts to ensure safe prescribing practices by following the CDC Guideline for Prescribing Opioids for Chronic Pain †††††† are enhanced by access to nonopioid and nonpharmacologic treatments for pain. Other important activities include increasing naloxone availability, expanding access to medication-assisted treatment, enhancing public health and public safety partnerships, and maximizing the ability of health systems to link persons to treatment and harm-reduction services. Summary What is already known about this topic? The U.S. opioid overdose epidemic continues to evolve. In 2016, 66.4% of the 63,632 drug overdose deaths involved an opioid. What is added by this report? In 2017, among 70,237 drug overdose deaths, 47,600 (67.8%) involved opioids, with increases across age groups, racial/ethnic groups, county urbanization levels, and in multiple states. From 2013 to 2017, synthetic opioids contributed to increases in drug overdose death rates in several states. From 2016 to 2017, synthetic opioid-involved overdose death rates increased 45.2%. What are the implications for public health practice? Continued federal, state, and local surveillance efforts to inform evidence-based prevention, response, and treatment strategies and to strengthen public health and public safety partnerships are urgently needed.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016

            This study uses National Vital Statistics System data to describe trends in synthetic opioid involvement in drug overdose deaths in the United States from 2010 to 2016.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants — United States, 2015–2016

              During 1999‒2015, 568,699 persons died from drug overdoses in the United States.* Drug overdose deaths in the United States increased 11.4% from 2014 to 2015 resulting in 52,404 deaths in 2015, including 33,091 (63.1%) that involved an opioid. The largest rate increases from 2014 to 2015 occurred among deaths involving synthetic opioids other than methadone (synthetic opioids) (72.2%) ( 1 ). Because of demographic and geographic variations in overdose deaths involving different drugs ( 2 , 3 ), † CDC examined age-adjusted death rates for overdoses involving all opioids, opioid subcategories (i.e., prescription opioids, heroin, and synthetic opioids), § cocaine, and psychostimulants with abuse potential (psychostimulants) by demographics, urbanization levels, and in 31 states and the District of Columbia (DC). There were 63,632 drug overdose deaths in 2016; 42,249 (66.4%) involved an opioid. ¶ From 2015 to 2016, deaths increased across all drug categories examined. The largest overall rate increases occurred among deaths involving cocaine (52.4%) and synthetic opioids (100%), likely driven by illicitly manufactured fentanyl (IMF) ( 2 , 3 ). Increases were observed across demographics, urbanization levels, and states and DC. The opioid overdose epidemic in the United States continues to worsen. A multifaceted approach, with faster and more comprehensive surveillance, is needed to track emerging threats to prevent and respond to the overdose epidemic through naloxone availability, safe prescribing practices, harm-reduction services, linkage into treatment, and more collaboration between public health and public safety agencies. Drug overdose deaths were identified in the National Vital Statistics System multiple cause-of-death mortality files,** using the International Classification of Diseases, Tenth Revision (ICD-10), based on ICD-10 underlying cause-of-death codes X40–44 (unintentional), X60–64 (suicide), X85 (homicide), or Y10–Y14 (undetermined intent). Among deaths with drug overdose as the underlying cause, the type of drug or drug category is indicated by the following ICD-10 multiple cause-of-death codes: opioids (T40.0, T40.1, T40.2, T40.3, T40.4, or T40.6) †† ; natural/semisynthetic opioids (T40.2); methadone (T40.3); heroin (T40.1); synthetic opioids other than methadone (T40.4); cocaine (T40.5); and psychostimulants with abuse potential (T43.6). Some deaths involved more than one type of drug; these deaths were included in the rates for each drug category. Therefore, categories are not mutually exclusive. §§ Age-adjusted overdose death rates ¶¶ were examined for 2015 and 2016 for all opioids, opioid subcategories (prescription opioids [i.e., natural/semisynthetic opioids and methadone] ( 4 ), heroin, and synthetic opioids), cocaine, and psychostimulants in the United States and by age, sex, racial/ethnic group, urbanization level,*** and state. State-level analyses included 31 states and DC that met the following criteria: 1) ≥80% of drug overdose death certificates named at least one specific drug in 2015 and 2016; 2) change from 2015 to 2016 in the percentage of death certificates reporting at least one specific drug was 10 percentage points in drug specificity. ¶¶ Absolute rate change is the difference between 2015 and 2016 rates. Percent change is the absolute rate change divided by the 2015 rate, multiplied by 100. Nonoverlapping confidence intervals based on the gamma method were used if the number of deaths was 10 percentage points in drug specificity. ¶¶ Absolute rate change is the difference between 2015 and 2016 rates. Percent change is the absolute rate change divided by the 2015 rate, multiplied by 100. Nonoverlapping confidence intervals based on the gamma method were used if the number of deaths was 10 percentage points in drug specificity. ¶¶ Absolute rate change is the difference between 2015 and 2016 rates. Percent change is the absolute rate change divided by the 2015 rate, multiplied by 100. Nonoverlapping confidence intervals based on the gamma method were used if the number of deaths was <100 in 2015 or 2016, and z-tests were used if the number of deaths was ≥100 in both 2015 and 2016. *** Statistically significant at 0.05 level. ††† Cells with ≤9 deaths are not reported. Rates based on <20 deaths are not considered reliable and not reported. From 2015 to 2016, opioid-involved deaths increased in males and females and among persons aged ≥15 years, whites, blacks, Hispanics, and Asian/Pacific Islanders. The largest relative rate change occurred among blacks (56.1%) (Table 1). The largest absolute rate increases of opioid-involved deaths and deaths involving synthetic opioids occurred among males aged 25–44 years and persons aged 25–34 years. However, deaths involving synthetic opioids increased in every subgroup examined (Table 2). Rates involving prescription opioids, heroin, cocaine, and psychostimulants increased for both sexes, whites, blacks, and most age groups (Table 1) (Table 2) (Table 3). Counties in large central and fringe metro areas experienced the largest absolute increases in deaths involving prescription and synthetic opioids, heroin, and cocaine; micropolitan areas experienced the largest increase in rates involving psychostimulants (Table 1) (Table 2) (Table 3). Opioid death rates differed across the 31 states and DC, with synthetic opioids driving increases in many states. ¶¶¶ Although several states experienced increases across drug categories, in many, the changes from 2015 to 2016 were not significant. Rates of deaths involving synthetic opioids ranged from 0.9 to 30.3 per 100,000, with the largest rates and increases concentrated in eastern states. New Hampshire (30.3 per 100,000), West Virginia (26.3), and Massachusetts (23.5) had the highest synthetic opioid death rates. Twenty states and DC experienced increases in overdose death rates involving synthetic opioids, with 10 experiencing increases by ≥100%; the largest such increase (392.3%) occurred in DC, followed by Illinois (227.3%) and Maryland (206.9%) (Table 2). Many states with large increases in synthetic opioid death rates also had large increases in rates involving other drug categories (e.g., Maryland, Virginia, and DC), including any opioid, prescription opioids (Table 1), heroin (Table 2), and cocaine (Table 3). Thirteen states and DC experienced significant increases in heroin-involved death rates, whereas a significant decrease (56.9%) occurred in New Hampshire (Table 2). In 2016, the highest rates were in DC (17.3 per 100,000), West Virginia (14.9), and Ohio (13.5). The rates of prescription opioid–involved overdose deaths significantly increased in seven states and DC, with the highest rates in West Virginia (19.7), Maryland (13.1), Maine (12.5), and Utah (12.5) (Table 1). The highest cocaine-involved overdose death rates occurred in DC (13.5), Rhode Island (10.7), and Ohio (10.1), with 15 states and DC experiencing a significant increase from 2015 (Table 3). Significant increases in overdose death rates from heroin, prescription opioids, and cocaine occurred primarily in states in the eastern part of the country. Fourteen states experienced significant increases in psychostimulant-involved overdose death rates. The highest rates were in midwestern and western states: Nevada (7.5), New Mexico (7.1), and Oklahoma (7.1) (Table 3). Discussion Drug overdoses resulted in 632,331 deaths from 1999 to 2016 in the United States, with 351,630 being opioid overdose deaths.**** The epidemic has continued to worsen, with deaths increasing from 2015 to 2016 across all drug categories examined. Opioid-involved overdoses accounted for two thirds of drug overdose deaths, with increases across age and racial/ethnic groups, urbanization levels, and in numerous states. The findings highlight wide state and regional variations. Some states (e.g., New Hampshire, Ohio, and West Virginia,) experienced the highest overdose death rates across multiple drug categories, and others (primarily in the Midwest and West) recorded the highest rates of psychostimulant-involved overdose deaths. In New Hampshire, although heroin-involved death rates declined from 2015 to 2016, deaths involving synthetic opioids increased, as they did in most states. In addition, in some states (e.g., Maryland, Rhode Island, and West Virginia), 2016 rates of prescription opioid–involved deaths were higher than were those involving heroin. These data highlight the persistent and multifaceted nature of overdoses. The first wave of opioid overdose deaths began in the 1990s and included prescription opioid deaths. †††† A second wave, which began in 2010, was characterized by heroin deaths ( 5 ). A third wave started in 2013, with deaths involving highly potent synthetic opioids, particularly IMF and fentanyl analogs ( 2 , 3 , 6 ). §§§§ Synthetic opioid-involved deaths in 2016 accounted for 30.5% of all drug overdose deaths and 45.9% of all opioid-involved deaths, with a 100% increase in the rate of these deaths compared with 2015. Synthetic opioids propelled increases with 19,413 deaths (more than any drug examined), and previous findings underscore the contribution of IMF. In addition, IMF is now being mixed into counterfeit opioid and benzodiazepine pills, heroin, and cocaine, likely contributing to increases in overdose death rates involving other substances ( 3 , 7 , 8 ). The findings in this report are subject to at least five limitations. First, at autopsy, substances tested for, and circumstances under which tests are performed to determine which drugs are present, vary by time and jurisdiction, and improvements in toxicologic testing might account for some reported increases. Second, 17% (2015) and 15% (2016) of drug overdose death certificates did not include the specific types of drugs involved, and the percentage of drug overdose death certificates with at least one drug specified varied widely by state, ranging from 52.5% to 99.3% in 2016. This variation limits rate comparisons between states. Third, because heroin and morphine are metabolized similarly ( 9 ), some heroin deaths might have been misclassified as morphine deaths, resulting in underreporting of heroin deaths. Fourth, potential race misclassification might lead to underestimates for certain categories, primarily for American Indian/Alaska Natives and Asian/Pacific Islanders. ¶¶¶¶ Finally, state-specific analyses are restricted to 31 states and DC, limiting generalizability. The ongoing and worsening drug overdose epidemic requires immediate attention and action. Faster access to data collected is needed to understand emerging threats in local communities and to tailor response activities. CDC’s Enhanced State Opioid Overdose Surveillance program funds 32 states and DC for more timely and comprehensive nonfatal and fatal overdose data, including funding for improved comprehensive toxicologic testing to identify emerging drug threats in opioid-involved fatal overdoses.***** Syndromic surveillance data allow communities to identify overdoses quickly ( 10 ). The State Unintentional Drug Overdose Reporting System provides improved collection of toxicology data to identify specific drugs involved ( 6 ), information gathered from death scene investigations, and risk factors associated with fatal overdoses. Given the continuing threat from prescription opioids and the evolving threat from illicit opioids and other substances, a multifaceted prevention approach is required. Efforts to ensure safe prescribing practices ††††† are enhanced by access to nonopioid and nonpharmacologic treatments for pain. Other important efforts include increasing naloxone availability, expanding access to medication-assisted treatment, and maximizing the ability of health systems to link persons to treatment and harm reduction services ( 10 ). CDC supports many of these efforts through the Prevention for States and Data-Driven Prevention Initiatives, §§§§§ which together support opioid overdose prevention efforts in 42 states and DC. Collaboration with law enforcement, first responders, and harm reduction partners is also important to understanding local variations in drug supply and lethality and to implementing a multisectoral prevention approach. Summary What is already known about this topic? From 1999 to 2015, the drug overdose epidemic resulted in approximately 568,699 deaths. In 2015, 52,404 drug overdose deaths occurred; 63.1% (33,091) involved an opioid. From 2014 to 2015, the age-adjusted opioid-involved death rate increased by 15.6%; the rapid increase in deaths was driven in large part by synthetic opioids other than methadone (e.g., fentanyl). What is added by this report? In 2016, there were 63,632 drug overdose deaths in the United States. Opioids accounted for 66.4% (42,249) of deaths, with increases across age groups, racial/ethnic groups, urbanization levels, and multiple states. Age-adjusted death rates for overdoses involving synthetic opioids other than methadone doubled from 2015 to 2016, and death rates from prescription opioids, heroin, cocaine, and psychostimulants also increased. What are the implications for public health practice? There is an urgent need to implement a multifaceted, collaborative public health and public safety approach. Building on existing resources, more rapidly available and comprehensive surveillance data are needed to track emerging drug threats to guide public action to prevent and respond to the epidemic through increased naloxone availability, harm reduction services, linkage into treatment (including medication-assisted treatment), safe prescribing practices, and supporting law enforcement strategies to reduce the illicit drug supply.
                Bookmark

                Author and article information

                Journal
                MMWR Morb Mortal Wkly Rep
                MMWR Morb. Mortal. Wkly. Rep
                WR
                Morbidity and Mortality Weekly Report
                Centers for Disease Control and Prevention
                0149-2195
                1545-861X
                01 November 2019
                01 November 2019
                : 68
                : 43
                : 967-973
                Affiliations
                Office of the Assistant Secretary for Health, U.S. Department of Health and Human Services, Washington, D.C.; Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee; Office of the Director, National Center for Injury Prevention and Control, CDC; Division of Overdose Prevention, National Center for Injury Prevention and Control, CDC.
                Author notes
                Corresponding author: Kumiko M. Lippold, Kumiko.lippold@ 123456hhs.gov , 202-205-5815.
                Article
                mm6843a3
                10.15585/mmwr.mm6843a3
                6822810
                31671083
                8c843c71-7747-4797-96d3-b885a1e922e3

                All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

                History
                Categories
                Full Report

                Comments

                Comment on this article